Cardio ThinkLab
 

Download APAC STRONG-HF Master Pack: First-hand Insights from Prof Mebazaa on Heart Failure Treatment Monitoring

Breaking news: The latest ESC heart failure guidelines 2023 now recommends the implementation of STRONG-HF regimen in their recent update. This includes the rapid uptitration of guideline-directed medical therapy, coupled with frequent monitoring of NT-proBNP levels, categorised as Class I B, which marks a significant stride forward in improving patient care standards.

Learn from the Master Pack to gain more insights on STRONG-HF now!

Master Pack Details

STRONG-HF primary outcomes infographic
APSC APAC HF Consensus (Gap report to follow)
Prof. Mebazaa’s HF plenary at APSC
Exclusive interviews with Prof Mebazaa and APAC KOLs
The latest insights in HF treatment monitoring

Submit the form and access the Master Pack.

The Master Pack features unlimited and free access to the latest STRONG-HF content, exclusively with Prof Mebazaa sharing his experiences and insights to help you master the latest concepts, processes, and tools in heart failure (HF) management.

It also features the Asian Pacific Society of Cardiology (APSC) HF Consensus and Gap Report for a first look at the unmet needs and recommendations for Asia Pacific.

Embrace this opportunity and register now!

Despite advancements in cardiac care, the readmission rates for HF have not improved since the 1980s
Card image cap

High readmission and all-cause death

One year Asian HF readmission and all-cause death rate1:

17.7%
HFpEF
38.7%
HFrEF
Card image cap

High mortality rate

One year crude Asian all-cause mortality rate2:

9.6%

Heart Failure affects 64.3 millions people worldwide3

Asian HF patients are nearly a decade younger than those in Western Europe and North America4

Heart Failure Prevalence Asia: 1.26–6.7%5

STRONG-HF: the evidence-based, post-acute heart failure treatment strategy you have been waiting for

The STRONG-HF biomarker-led therapeutic strategy offers guidance on rapid induction and optimization of GDMT during the vulnerable period before and after discharge; thereby supporting HCPs in providing optimal, life-saving treatment when it is needed the most.

STRONG-HF study design

STRONG-HF results show that in the high intensity care group: 34% relative and 8.1 % absolute risk reduction (ARR) in the combination of death or heart failure readmission6.

CV (cardiovascular) death

26% lower

HF readmission

44% lower

All-cause death

16% lower

HF management has finally been mapped out with proven positive outcomes

Master Pack Details

STRONG-HF primary outcomes infographic
APSC APAC HF Consensus (Gap report to follow)
Prof. Mebazaa’s HF plenary at APSC
Exclusive interviews with Prof Mebazaa and APAC KOLs
The latest insights in HF treatment monitoring

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy.

28 March 2023
Prof Alexandre Mebazaa

CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021
Dr James L Januzzi